Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of DS-8201a in HER2-positive unresectable/metastatic breast cancer
2016-004986-18Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate (ORR). Started Oct 2017; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004986-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004986-18.